ArticleNature chemistry2026
Palladium-triggered bioorthogonal phenylalanine decaging.
Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Phenylalanine (Phe) orchestrates protein interfacial hydrophobicity and π-driven interactions that are critical for diverse biological processes. Its nonpolar architecture, however, precludes traditional heteroatom-dependent reactions, leaving its functional manipulation in living systems unresolved. Here, by systematically evaluating exogenous heteroatom-based (X = O, N, B or I) caging groups under physiological conditions, we present a haloatom-assisted decaging strategy that uses iodine to cage Phe's side chain. This blockade can be tracelessly rescued through palladium-triggered bioorthogonal decaging. Through precise modulation, the haloatom-assisted decaging strategy enables: unmasking fluorophore activity, directing peptide disassembly, reactivating protein-protein interactions and rewiring cell-cell recognition. Using genetic code expansion, we site-specifically incorporated iodinated Phe into HER2-targeting affibodies for dynamic control of ligand-receptor interaction on the cell surface. Moreover, Phe decaging permits temporally controlled reshaping of antigenic peptide immunogenicity on tumour cells, thereby rewiring tumour-T cell engagement. We further optimized the decaging chemistry in cell lysates as well as inside living cells, which unlocks the possibility of chemically manipulating ubiquitous and functionally critical nonpolar groups in living systems.
Identifiers
42686833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.